AP-2β CRISPR Activation Plasmid (h): sc-401846-ACT

TFAP2B encodes the human transcription factor AP-2β, a sequence-specific DNA-binding regulator that modulates gene expression programs controlling cellular differentiation, proliferation, and developmental patterning. AP-2β influences transcriptional networks that intersect with growth factor signaling and lineage-specifying pathways, shaping context-dependent responses in neural crest–derived tissues and other developmental compartments. Altered TFAP2B activity has been linked to congenital developmental disorders and dysregulated transcriptional states relevant to cancer biology, supporting its utility as a node for studying aberrant gene regulatory circuitry. Researchers often interrogate AP-2β to map downstream target genes, define enhancer-promoter logic, and understand how transcription factor dosage affects cell fate decisions.

AP-2β CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous TFAP2B expression without altering the underlying DNA sequence.

AP-2β CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the TFAP2B locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the TFAP2B transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous AP-2β expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native TFAP2B locus and enabling the study of AP-2β-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of AP-2β pathway restoration in tumor cells with silenced or reduced TFAP2B expression.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.